Baird analyst Brian Skorney noted the discourse surrounding the Aimmune regulatory approval has quickly shifted to a debate around commercial uptake. The analyst noted shorting the launch of a new product works nine out of ten times, but he believes this is different given the company's strong cash position and conservative first year estimates. He also believes the FDA review has effectively de-risked approval, moving into serious consideration as an acquisition candidate. Skorney reiterated his Outperform rating and $64 price target on Aimmune shares.